PL2809329T3 - Skrobia hydroksyalkilowa w połączeniu z cytostatykiem do leczenia raków poprzez zmniejszenie szybkości wzrostu guza - Google Patents

Skrobia hydroksyalkilowa w połączeniu z cytostatykiem do leczenia raków poprzez zmniejszenie szybkości wzrostu guza

Info

Publication number
PL2809329T3
PL2809329T3 PL13714546T PL13714546T PL2809329T3 PL 2809329 T3 PL2809329 T3 PL 2809329T3 PL 13714546 T PL13714546 T PL 13714546T PL 13714546 T PL13714546 T PL 13714546T PL 2809329 T3 PL2809329 T3 PL 2809329T3
Authority
PL
Poland
Prior art keywords
cytostatica
cancers
reduction
treatment
combination
Prior art date
Application number
PL13714546T
Other languages
English (en)
Inventor
Martin Westphal
Silke Baasner
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PL2809329T3 publication Critical patent/PL2809329T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13714546T 2012-01-30 2013-01-30 Skrobia hydroksyalkilowa w połączeniu z cytostatykiem do leczenia raków poprzez zmniejszenie szybkości wzrostu guza PL2809329T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592017P 2012-01-30 2012-01-30
EP12153068 2012-01-30
PCT/EP2013/000276 WO2013113496A1 (en) 2012-01-30 2013-01-30 Hydroxyalkyl starch in combination with cytostatica for the treatment of cancers by reduction of tumor growth rates
EP13714546.2A EP2809329B1 (en) 2012-01-30 2013-01-30 Hydroxyalkyl starch in combination with cytostatica for the treatment of cancers by reduction of tumor growth rates

Publications (1)

Publication Number Publication Date
PL2809329T3 true PL2809329T3 (pl) 2019-01-31

Family

ID=48870742

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13706932T PL2809328T3 (pl) 2012-01-30 2013-01-30 Skrobia hydroksyalkilowa do leczenia nowotworów głowy i szyi przez zmniejszenie szybkości wzrostu guza
PL13701646T PL2809327T3 (pl) 2012-01-30 2013-01-30 Skrobia hydroksyetylowa do leczenia nowotworów przez zmniejszenie szybkości wzrostu guza
PL13714546T PL2809329T3 (pl) 2012-01-30 2013-01-30 Skrobia hydroksyalkilowa w połączeniu z cytostatykiem do leczenia raków poprzez zmniejszenie szybkości wzrostu guza

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL13706932T PL2809328T3 (pl) 2012-01-30 2013-01-30 Skrobia hydroksyalkilowa do leczenia nowotworów głowy i szyi przez zmniejszenie szybkości wzrostu guza
PL13701646T PL2809327T3 (pl) 2012-01-30 2013-01-30 Skrobia hydroksyetylowa do leczenia nowotworów przez zmniejszenie szybkości wzrostu guza

Country Status (12)

Country Link
US (4) US20130196949A1 (pl)
EP (3) EP2809328B1 (pl)
CN (1) CN104080463B (pl)
AU (3) AU2013214567B2 (pl)
CA (2) CA2861084A1 (pl)
DK (2) DK2809327T3 (pl)
ES (3) ES2698272T3 (pl)
HR (1) HRP20181754T1 (pl)
LT (2) LT2809327T (pl)
PL (3) PL2809328T3 (pl)
SI (2) SI2809327T1 (pl)
WO (3) WO2013113747A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2658400T3 (es) 2013-07-30 2018-03-09 Fresenius Kabi Deutschland Gmbh Almidón hidroxialquilado para el tratamiento de neoplasias hematológicas
EP2832360A1 (en) * 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse
CN105311051A (zh) * 2014-05-26 2016-02-10 陈松源 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径
EA034858B1 (ru) * 2015-01-30 2020-03-30 Фрезениус Каби Дойчланд Гмбх Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919729C3 (de) 1989-06-16 1997-06-19 Fresenius Ag Hydroxyethylstärke als Plasmaexpander, Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
DE4023788A1 (de) * 1990-07-26 1992-01-30 Schumann Klaus Verwendung einer waessrigen loesung einer poly-(o-hydroxyalkyl)-staerke
DE4310974C2 (de) 1993-04-03 1996-08-01 Fresenius Ag Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
US6680305B1 (en) 1993-06-04 2004-01-20 Biotime, Inc. Physiologically acceptable aqueous solutions and methods for their use
EP0831806A1 (en) 1995-06-07 1998-04-01 Washington University Multidentate metal complexes and methods of making and using thereof
US6207654B1 (en) * 1996-05-03 2001-03-27 Bashir Zikria Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2
DE19907257A1 (de) 1999-02-21 2000-09-14 Bernd Horst Meier Mittel zur Steuerung der Diffusion von Injektionslösungen
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
EP1732953B1 (de) 2004-03-01 2007-11-07 B. Braun Melsungen Ag Hydroxyethylstärke
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101926770B (zh) * 2009-06-25 2013-07-10 浙江海正药业股份有限公司 载药脂质体及其制备方法
CN101926773B (zh) * 2009-06-25 2013-04-03 浙江海正药业股份有限公司 载药类脂微粒及其制备方法
EP2590677A1 (en) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
EP2590678A1 (en) * 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
US20130197211A1 (en) 2013-08-01
EP2809329B1 (en) 2018-08-01
WO2013113765A1 (en) 2013-08-08
CA2861161C (en) 2020-12-29
LT2809329T (lt) 2018-12-10
CA2861084A1 (en) 2013-08-08
US20130196949A1 (en) 2013-08-01
HK1202807A1 (en) 2015-10-09
CN104080463B (zh) 2020-07-10
LT2809327T (lt) 2018-11-26
SI2809329T1 (sl) 2018-12-31
ES2693288T3 (es) 2018-12-10
CA2861161A1 (en) 2013-08-08
PL2809328T3 (pl) 2019-01-31
DK2809327T3 (en) 2018-11-26
EP2809327A1 (en) 2014-12-10
AU2013214313A1 (en) 2014-07-17
AU2013214567A1 (en) 2014-07-17
CN104080463A (zh) 2014-10-01
US20160082036A1 (en) 2016-03-24
ES2698272T3 (es) 2019-02-01
AU2013214295B2 (en) 2017-04-06
HRP20181754T1 (hr) 2018-12-28
DK2809329T3 (en) 2018-11-26
EP2809328B1 (en) 2018-08-01
AU2013214313B2 (en) 2017-04-06
EP2809329A1 (en) 2014-12-10
EP2809328A1 (en) 2014-12-10
AU2013214567B2 (en) 2017-06-08
WO2013113496A1 (en) 2013-08-08
AU2013214295C1 (en) 2017-07-27
AU2013214295A1 (en) 2014-07-17
PL2809327T3 (pl) 2019-02-28
WO2013113747A1 (en) 2013-08-08
ES2698948T3 (es) 2019-02-06
US20130197212A1 (en) 2013-08-01
EP2809327B1 (en) 2018-08-01
SI2809327T1 (sl) 2018-12-31

Similar Documents

Publication Publication Date Title
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
IL239007A0 (en) Use of Aribolin to treat breast cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
IL238942B (en) History of pyrimidine-4,2-diamine for cancer treatment
IL235726A0 (en) Pyrimidine compounds for cancer treatment
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
PT3400943T (pt) Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2.
IL263781A (en) Combined treatment of ovarian cancer
IL238116B (en) A process for preparing compounds for use in the treatment of cancer
LT2809329T (lt) Hidroksialkilo krakmolas derinyje su citostatikais, skirti vėžio gydymui, simažinant naviko augimo greičius
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
PT2809329T (pt) Hidroxialquilamido em combinação com citostáticos para o tratamento do cancro por redução das taxas de crescimento tumoral
GB2507765B8 (en) Substituted pyridine derivatives useful in the treatment of cancer
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
PT2925744T (pt) Derivados de pirimidina-2,4-diamina para tratamento de cancro